Contribution: Industrial Research Assistance Program – Contributions to Firms
MESHMD INC.
$160,000.00
Development of Hepatitis C Omnibus Portal (hepMD)
FY 2019-20 · 2019-10-01
Summary
The hepMD platform will eliminate cumbersome paperwork and allow health care providers to quickly get their patients on to one of the new oral HCV therapies - Vosevi (Gilead Sciences Canada), Zepatier (Merck Canada), Maviret (Abbvie Canada). The portal will bring blockchain to prescription management as a novel way of dealing with the very problematic issue related to digitally prescribing pharmaceuticals in Canada.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Toronto|Toronto, Ontario, Canada
Recipient Type
For-profit organization
Business Number
859789620
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2019-10-01 | 2019-20 | $160,000.00 |
| 1 | 2019-10-01 | 2019-20 | $160,000.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 92 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 92 jours.
Agreement End Date
2021-01-31
Agreement Number
935347
Agreement Start Date
2019-10-01
Agreement Title
Development of Hepatitis C Omnibus Portal (hepMD)
Agreement Title (French)
Développement d'un portail général sur l'hépatite C (hepMD)
Agreement Type
Contribution
Agreement Value
$160,000.00
Amendment Date
2020-07-06
Amendment Number
1
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
The hepMD platform will eliminate cumbersome paperwork and allow health care providers to quickly get their patients on to one of the new oral HCV therapies - Vosevi (Gilead Sciences Canada), Zepatier (Merck Canada), Maviret (Abbvie Canada). The portal will bring blockchain to prescription management as a novel way of dealing with the very problematic issue related to digitally prescribing pharmaceuticals in Canada.
Description (French)
La plate-forme hepMD éliminera la paperasserie encombrante et permettra aux fournisseurs de soins de santé d'orienter rapidement leurs patients vers l'un des nouveaux traitements oraux contre le VHC - Vosevi (Gilead Sciences Canada), Zepatier (Merck Canada), Maviret (Abbvie Canada). Le portail apportera la technologie de la chaîne de blocs à la gestion des ordonnances comme nouvelle façon de traiter la question très problématique de prescription numérique des produits pharmaceutiques au Canada.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Eglinton--Lawrence
Federal Riding (French)
Eglinton--Lawrence
Federal Riding Number
35024
NAICS Code
54151
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
859789620
Recipient City
Toronto|Toronto
Recipient Country
CA
Recipient Legal Name
MESHMD INC.
Recipient Postal Code
M6B 1W3
Recipient Province or Territory
ON
Recipient Type
F
Reference Number
172-2019-2020-Q3-935347
